Lung cancer is the most common malignancy tumor. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer. Human epidermal growth factor receptor-2 (HER2) is a tyrosine kinase receptor in ERBB/HER family, which activates downstream signal transduction with other family members such as epidermal growth factor receptor (EGFR). HER2 gene mutation is closely related to the progression of many epithelial cell cancers. Tumors with high expression of HER2 show strong metastasis and invasion ability, poor sensitivity to chemotherapy, and are prone to relapse. At present, lung cancer driven gene targeted therapy has made rapid progress. Although the frequency of HER2 gene mutation in NSCLC is lower than that of EGFR, its driving mechanism in lung cancer is clear and partial targeted therapy is effective, which may become a new standard treatment in the future. This review focuses on the research progress of HER2 gene mutation in the treatment of NSCLC. .
【中文题目：晚期非小细胞肺癌HER2基因突变 靶向治疗进展】 【中文摘要：肺癌是最常见的恶性肿瘤，非小细胞肺癌（non-small cell lung cancer, NSCLC）发生率约占所有肺癌的85%。人表皮生长因子受体2（human epidermal growth factor receptor-2, HER2）是ERBB/HER家族中的一种酪氨酸激酶受体，与表皮生长因子受体（epidermal growth factor receptor, EGFR）等其他家族成员一起激活下游信号传导。HER2基因突变与许多上皮细胞癌症的恶化程度密切相关，HER2基因突变的肿瘤表现出较强的转移能力和侵润能力，对化疗的敏感性也较差，且易复发。目前肺癌驱动基因靶向治疗进展迅速。作为驱动基因，NSCLC中HER2基因突变频率相对于EGFR较低，但是其肺癌驱动机制明确且部分靶向治疗有效，将来可能成为新的标准治疗手段。本文重点讨论HER2基因突变在NSCLC治疗中的研究进展。 】 【中文关键词：肺肿瘤；人表皮生长因子受体-2；酪氨酸激酶抑制剂；抗体-药物偶联物】.
Keywords: Antibody-drug conjugate; Human epidermal growth factor receptor-2; Lung neoplasms; Tyrosine kinase inhibitor.